MetaVia MTVA
NASDAQ MTVA
$1.46 +0.02 (+1.39%)
At close: Aug 21, 2026 · 4:00 PM EDT

MetaVia (MTVA) Cash from Financing Activities (2015 - 2025)

MetaVia's (MTVA) quarterly Cash from Financing Activities came in at $861000.0 in Q4 2025, up 570.49% YoY from $128413.2 in Q4 2024, and up 341.18% on a QoQ basis from -$357000.0 in Q3 2025.

MetaVia (MTVA) Cash from Financing Activities (2015 - 2025) Analysis & Trends

MetaVia (MTVA) has 10 years of Cash from Financing Activities data on file, last reported at $861000.0 in Q4 2025.

  • Quarterly Cash from Financing Activities rose 570.49% year-over-year to $861000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10.0 million (up 1207.11% YoY) and the FY2025 annual result came in at $10.0 million, down 45.55% from the prior year.
  • Cash from Financing Activities rose to $861000.0 in Q4 2025, from -$357000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $28.8 million in Q4 2022 to a low of -$717000.0 in Q3 2024.
  • A 4-year average of $5.4 million and a median of $72000.0 in 2021 frame the typical range for Cash from Financing Activities.
  • The widest YoY moves for Cash from Financing Activities: up 17054.72% in 2021, down 98.94% in 2021.
  • Tracing MTVA's Cash from Financing Activities over 4 years: stood at $12.9 million in 2021, then soared by 123.61% to $28.8 million in 2022, then tumbled by 100.64% to -$183000.0 in 2024, then surged by 570.49% to $861000.0 in 2025.
  • The last three Cash from Financing Activities figures came in at $861000.0 (Q4 2025), -$357000.0 (Q3 2025), and $9.5 million (Q2 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -426.70 Mn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn -1.22 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 14.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn -6.05 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 36.24 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -16.65 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 27.18 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - -273.15 Mn
10 MetaVia 8.72 Mn -3.92 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2025 861,000.00
Dec 31, 2025 861,000.00
Sep 30, 2025 -357,000.00
Sep 30, 2025 -357,000.00
Jun 30, 2025 9.47 Mn
Jun 30, 2025 9.47 Mn
Mar 31, 2025 -12,000.00
Mar 31, 2025 -12,000.00
Dec 31, 2024 -183,000.00
Dec 31, 2024 -183,000.00
Sep 30, 2024 -717,000.00
Sep 30, 2024 -717,000.00
Dec 31, 2022 28.82 Mn
Dec 31, 2022 28.82 Mn
Dec 31, 2021 12.89 Mn
Dec 31, 2021 12.89 Mn
Sep 30, 2021 -24,000.00
Sep 30, 2021 -24,000.00
Jun 30, 2021 72,000.00
Jun 30, 2021 72,000.00